These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 31371343)

  • 1.
    Drago JZ; Formisano L; Juric D; Niemierko A; Servetto A; Wander SA; Spring LM; Vidula N; Younger J; Peppercorn J; Yuen M; Malvarosa G; Sgroi D; Isakoff SJ; Moy B; Ellisen LW; Iafrate AJ; Arteaga CL; Bardia A
    Clin Cancer Res; 2019 Nov; 25(21):6443-6451. PubMed ID: 31371343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
    Formisano L; Lu Y; Servetto A; Hanker AB; Jansen VM; Bauer JA; Sudhan DR; Guerrero-Zotano AL; Croessmann S; Guo Y; Ericsson PG; Lee KM; Nixon MJ; Schwarz LJ; Sanders ME; Dugger TC; Cruz MR; Behdad A; Cristofanilli M; Bardia A; O'Shaughnessy J; Nagy RJ; Lanman RB; Solovieff N; He W; Miller M; Su F; Shyr Y; Mayer IA; Balko JM; Arteaga CL
    Nat Commun; 2019 Mar; 10(1):1373. PubMed ID: 30914635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.
    O'Leary B; Cutts RJ; Huang X; Hrebien S; Liu Y; André F; Loibl S; Loi S; Garcia-Murillas I; Cristofanilli M; Bartlett CH; Turner NC
    J Natl Cancer Inst; 2021 Mar; 113(3):309-317. PubMed ID: 32940689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
    Ladd B; Mazzola AM; Bihani T; Lai Z; Bradford J; Collins M; Barry E; Goeppert AU; Weir HM; Hearne K; Renshaw JG; Mohseni M; Hurt E; Jalla S; Bao H; Hollingsworth R; Reimer C; Zinda M; Fawell S; D'Cruz CM
    Oncotarget; 2016 Aug; 7(34):54120-54136. PubMed ID: 27472462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
    Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
    Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
    [No Abstract]   [Full Text] [Related]  

  • 7. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
    Xi J; Ma CX
    Curr Oncol Rep; 2020 May; 22(6):57. PubMed ID: 32415339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
    Yardley DA; Liggett W; Mainwaring M; Castrellon A; Blakely L; Hemphill B; Anz B; Young RR; Shastry M; DeBusk LM; Hainsworth JD; Burris HA
    Clin Breast Cancer; 2020 Apr; 20(2):89-97. PubMed ID: 31932237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy.
    Cabel L; Rosenblum D; Lerebours F; Brain E; Loirat D; Bergqvist M; Cottu P; Donnadieu A; Bethune A; Kiavue N; Rodrigues M; Pierga JY; Tanguy ML; Bidard FC
    Breast Cancer Res; 2020 Sep; 22(1):98. PubMed ID: 32928264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palbociclib combined with endocrine therapy in heavily pretreated HR
    Manso L; Hernando C; Galán M; Oliveira M; Cabrera MA; Bratos R; Rodríguez CA; Ruiz-Borrego M; Blanch S; Llombart-Cussac A; Delgado-Mingorance JI; Álvarez-Busto I; Gallegos I; González-Cortijo L; Morales S; Aguirre E; Hernando BA; Ballesteros A; Alés-Martínez JE; Reboredo C; Oltra A; González-Cao M; Santisteban M; Malón D; Echeverría I; García-Garre E; Vega E; Servitja S; Andrés R; Robles CE; López R; Galve E; Echarri MJ; Legeren M; Moreno F
    Breast; 2020 Dec; 54():286-292. PubMed ID: 33242755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER
    Mao P; Cohen O; Kowalski KJ; Kusiel JG; Buendia-Buendia JE; Cuoco MS; Exman P; Wander SA; Waks AG; Nayar U; Chung J; Freeman S; Rozenblatt-Rosen O; Miller VA; Piccioni F; Root DE; Regev A; Winer EP; Lin NU; Wagle N
    Clin Cancer Res; 2020 Nov; 26(22):5974-5989. PubMed ID: 32723837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
    Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
    Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
    Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
    Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.
    Cristofanilli M; DeMichele A; Giorgetti C; Turner NC; Slamon DJ; Im SA; Masuda N; Verma S; Loi S; Colleoni M; Theall KP; Huang X; Liu Y; Bartlett CH
    Eur J Cancer; 2018 Nov; 104():21-31. PubMed ID: 30308388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
    Pritchard KI; Chia SK; Simmons C; McLeod D; Paterson A; Provencher L; Rayson D
    Oncologist; 2017 Jan; 22(1):12-24. PubMed ID: 27864574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1.
    Mouron S; Manso L; Caleiras E; Rodriguez-Peralto JL; Rueda OM; Caldas C; Colomer R; Quintela-Fandino M; Bueno MJ
    Breast Cancer Res; 2021 Feb; 23(1):21. PubMed ID: 33579347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
    Vernieri C; Corti F; Nichetti F; Ligorio F; Manglaviti S; Zattarin E; Rea CG; Capri G; Bianchi GV; de Braud F
    Breast Cancer Res; 2020 Apr; 22(1):33. PubMed ID: 32252811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients.
    Darrigues L; Pierga JY; Bernard-Tessier A; Bièche I; Silveira AB; Michel M; Loirat D; Cottu P; Cabel L; Dubot C; Geiss R; Ricci F; Vincent-Salomon A; Proudhon C; Bidard FC
    Breast Cancer Res; 2021 Mar; 23(1):31. PubMed ID: 33676547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
    O'Brien NA; McDermott MSJ; Conklin D; Luo T; Ayala R; Salgar S; Chau K; DiTomaso E; Babbar N; Su F; Gaither A; Hurvitz SA; Linnartz R; Rose K; Hirawat S; Slamon DJ
    Breast Cancer Res; 2020 Aug; 22(1):89. PubMed ID: 32795346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
    Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.